NYSE$HAE

Haemonetics Corp. · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Haemonetics' Q3 2021 financial results were reported, showing revenue decrease but improved profitability driven by Operational Excellence Program and cost management.

Haemonetics reported a 7.2% decrease in revenue to $240.4 million for Q3 2021, impacted by COVID-19. However, profitability improved due to the Operational Excellence Program and cost management. The company is progressing with NexSys® and TEG® adoption and investing in innovation.

  • Q3 revenue decreased by 7% to $240 million.
  • Earnings per diluted share was $0.62, while adjusted earnings per diluted share was $0.81.
  • Gross margin was 50.0%, up 60 basis points compared to the prior year.
  • Operating income was $40.4 million, with an operating margin of 16.8%.

Headline financials

Total Revenue

$240M

Previous: $259M-7.2%
EPS (adj)

$0.81

Previous: $0.94-13.8%
Capital Expenditures

-$25.4M

Previous: -$38.1M+33.3%
Free Cash Flow

$6.47M

Previous: -$8.22M+178.8%
Net Income

$31.9M

Previous: $29.9M+6.6%
Operating Income

$40.4M

Previous: $40.9M-1.2%
Gross Profit

$120M

Previous: $128M-6.1%
Cash & Equivalents

$189M

Previous: $126M+49.5%
Total Assets

$1.32B

Previous: $1.24B+6.5%
Stock-Based Comp

$6.29M

Previous: $5.33M+18.1%

Revenue & EPS history

Haemonetics · Revenue · Quarterly

$240M

Q3 2021-7.2%vs Q3 2020
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Haemonetics · $236M total across 3 segments · Q3 2021

  • Plasma
    $102M-15.4%
  • Blood Center
    $80.9M-3.0%
  • Hospital
    $52.7M+4.7%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+1.4%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+6.5%

Avg return

30 days after

56%

38 / 68 earnings

Positive

+31.8%

Q2 2026

Best reaction

-15.0%

Q4 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+3.3%+2.5%+35.5%
Q3 2026-1.4%-9.8%-2.8%
Q2 2026+31.8%+41.4%+65.5%
Q4 2025+5.9%+7.6%+9.7%
Q3 2025-11.6%-13.6%-3.6%
Q2 2025+11.8%+19.5%+3.9%
Q1 2025-10.1%-13.4%-14.6%
Q4 2024+2.8%+4.4%-8.2%
Q3 2024-3.8%-7.0%+3.2%
Q2 2024+2.4%+2.5%-2.5%
Q1 2024+2.0%+3.0%-0.8%
Q4 2023+7.6%+7.4%+6.1%
Q3 2023-5.4%-8.2%-12.2%
Q2 2023+4.1%-1.7%+3.5%
Q1 2023+8.1%+12.3%+13.7%
Q4 2022+3.9%+14.1%+31.5%
Q3 2022+21.2%+24.5%+18.9%
Q2 2022-13.5%-15.7%-24.8%
Q1 2022+8.4%+1.8%+16.8%
Q4 2021-6.4%-5.4%+0.4%
Q3 2021+12.8%+21.1%+4.0%
Q2 2021-3.7%+5.6%+13.2%
Q1 2021-12.7%-8.5%+3.3%
Q4 2020-8.8%-3.4%-11.1%
Q3 2020+7.2%+7.7%-7.3%
Q2 2020+0.3%+0.5%-0.1%
Q1 2020+10.5%+13.5%+10.8%
Q4 2019+2.8%+3.4%+10.0%
Q3 2019-12.2%-14.3%-13.0%
Q2 2019+9.1%+5.8%-0.2%
Q1 2019+4.8%+2.7%+14.4%
Q4 2018+5.8%+11.2%+18.9%
Q3 2018+14.8%+13.1%+20.5%
Q2 2018+15.8%+16.4%+20.8%
Q1 2018+4.2%+3.2%+3.9%
Q4 2017-1.9%-4.4%-4.0%
Q3 2017-10.1%-9.0%-7.3%
Q2 2017+10.5%+13.8%+16.5%
Q1 2017+13.8%+16.8%+22.6%
Q4 2016-15.0%
Q3 2016+5.9%
Q2 2016-3.9%
Q1 2016+1.5%
Q4 2015-3.9%
Q3 2015+7.0%
Q2 2015-5.9%
Q1 2015-1.4%
Q4 2014-8.0%
Q3 2014-2.6%
Q2 2014+1.5%
Q1 2014+0.7%
Q4 2013-1.4%
Q3 2013-5.6%
Q2 2013+4.3%
Q1 2013-0.1%
Q4 2012+4.2%
Q3 2012-1.0%
Q2 2012+0.4%
Q1 2012+3.1%
Q4 2011+1.3%
Q4 2009+1.3%
Q3 2010-1.3%
Q3 2011-1.3%
Q2 2011+1.7%
Q1 2010-2.5%
Q2 2010-2.5%
Q1 2011-2.5%
Q4 2010-2.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro